AstraZeneca PLC (LON:AZN) Receives £104.12 Consensus Target Price from Brokerages

Shares of AstraZeneca PLC (LON:AZN - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine research firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is £104.12 ($132.83).

AZN has been the subject of several research reports. Shore Capital reaffirmed a "buy" rating on shares of AstraZeneca in a report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a £110 ($140.32) target price on shares of AstraZeneca in a report on Tuesday, September 3rd. JPMorgan Chase & Co. reissued an "overweight" rating and issued a £140 ($178.59) price target on shares of AstraZeneca in a report on Friday, November 22nd. Finally, Berenberg Bank restated a "buy" rating and set a £150 ($191.35) price objective on shares of AstraZeneca in a report on Monday, September 2nd.

AstraZeneca Stock Up 0.2 %

Shares of AstraZeneca stock traded up GBX 26 ($0.33) on Wednesday, reaching £105.38 ($134.43). 3,047,915 shares of the company were exchanged, compared to its average volume of 3,864,687. The company has a market capitalization of £163.34 billion, a price-to-earnings ratio of 3,349.21, a PEG ratio of 0.86 and a beta of 0.17. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97. AstraZeneca has a one year low of GBX 9,461 ($120.69) and a one year high of £133.88 ($170.79). The company has a 50-day moving average of £110.21 and a 200 day moving average of £119.29.

Insider Buying and Selling at AstraZeneca

In other news, insider Pascal Soriot bought 20,000 shares of the company's stock in a transaction that occurred on Thursday, November 14th. The shares were acquired at an average price of £102.03 ($130.16) per share, for a total transaction of £2,040,600 ($2,603,138.16). Also, insider Michel Demare purchased 2,000 shares of the business's stock in a transaction on Friday, September 13th. The shares were purchased at an average cost of GBX 118 ($1.51) per share, for a total transaction of £2,360 ($3,010.59). In the last ninety days, insiders acquired 23,500 shares of company stock worth $223,316,000. 0.04% of the stock is currently owned by company insiders.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.